{
    "ticker": "IMRN",
    "name": "Immunome, Inc.",
    "description": "Immunome, Inc. is a biotechnology company dedicated to harnessing the power of the human immune system to create transformative therapies for cancer and other serious diseases. Founded in 2009 and headquartered in Exton, Pennsylvania, Immunome utilizes its proprietary platform to develop monoclonal antibodies that target a broad range of diseases. The company's unique approach involves leveraging the natural immune response of cancer patients to identify potent therapeutic antibodies. This innovative methodology not only enhances the specificity and efficacy of the treatments but also reduces the potential for adverse effects commonly associated with conventional therapies. Immunome's lead product candidate, IMM-101, is currently in clinical trials for the treatment of various cancers, including pancreatic and breast cancer. By focusing on the immune system's capabilities, Immunome aims to provide patients with more effective treatment options and improve survival rates. The company is committed to advancing the field of immunotherapy, empowering patients with new hope through cutting-edge research and development.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Exton, Pennsylvania, USA",
    "founded": "2009",
    "website": "https://www.immunome.com",
    "ceo": "Pablo J. Cagnoni",
    "social_media": {
        "twitter": "https://twitter.com/immunome",
        "linkedin": "https://www.linkedin.com/company/immunome/"
    },
    "investor_relations": "https://ir.immunome.com",
    "key_executives": [
        {
            "name": "Pablo J. Cagnoni",
            "position": "CEO"
        },
        {
            "name": "Jared S. M. S. Pillon",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutic Candidates",
            "products": [
                "IMM-101"
            ]
        },
        {
            "category": "Research and Development",
            "products": [
                "Monoclonal Antibodies"
            ]
        }
    ],
    "seo": {
        "meta_title": "Immunome, Inc. | Innovative Immunotherapy Solutions",
        "meta_description": "Discover Immunome, Inc., a biotechnology company focused on developing immune-based therapies for cancer and serious diseases. Learn about their innovative approach and lead product candidate, IMM-101.",
        "keywords": [
            "Immunome",
            "Biotechnology",
            "Immunotherapy",
            "Cancer Treatment",
            "Monoclonal Antibodies",
            "IMM-101"
        ]
    },
    "faq": [
        {
            "question": "What is Immunome known for?",
            "answer": "Immunome is known for developing innovative therapies leveraging the human immune system, particularly monoclonal antibodies for cancer treatment."
        },
        {
            "question": "Who is the CEO of Immunome?",
            "answer": "Pablo J. Cagnoni is the CEO of Immunome, Inc."
        },
        {
            "question": "Where is Immunome headquartered?",
            "answer": "Immunome is headquartered in Exton, Pennsylvania, USA."
        },
        {
            "question": "What is Immunome's lead product candidate?",
            "answer": "Immunome's lead product candidate is IMM-101, which is in clinical trials for various cancers."
        },
        {
            "question": "When was Immunome founded?",
            "answer": "Immunome was founded in 2009."
        }
    ],
    "competitors": [
        "BMY",
        "AMGN",
        "REGN",
        "EXEL"
    ],
    "related_stocks": [
        "NVAX",
        "GILD",
        "MRNA",
        "PFE"
    ]
}